N. Polerà

发表

From Vegetable Waste to New Agents for Potential Health Applications: Antioxidant Properties and Effects of Extracts, Fractions and Pinocembrin from Glycyrrhiza glabra L. Aerial Parts on Viability of Five Human Cancer Cell Lines.

M. Bonesi, R. Tundis, M. Loizzo, 2017, Journal of agricultural and food chemistry.

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma

P. Tassone, P. Tagliaferri, M. Arbitrio, 2022, International journal of molecular sciences.

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin

P. Tassone, P. Tagliaferri, F. Vasile, 2022, Journal of Translational Medicine.

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

P. Tassone, P. Tagliaferri, A. Giordano, 2021, Journal for ImmunoTherapy of Cancer.

In vitro anti-proliferative and anti-bacterial properties of new C7 benzoate derivatives of pinocembrin

I. Casaburi, R. Tundis, M. Loizzo, 2019, Natural product research.

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells

P. Tassone, P. Tagliaferri, S. Sestito, 2022, Cancers.

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives

P. Tassone, P. Tagliaferri, D. Caracciolo, 2023, Experimental Hematology & Oncology.

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy

P. Tassone, P. Tagliaferri, M. Arbitrio, 2021, Cancers.

Quercetin and its Natural Sources in Wound Healing Management.

F. Aiello, M. Badolato, G. Carullo, 2018, Current medicinal chemistry.

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

P. Tassone, P. Tagliaferri, M. Gaspari, 2020, Leukemia.

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Cancers.

A First-in-Class Pronectin™-based Bispecific T Cell Engager Anti-AXL x CD3 for the Treatment of Epithelial Ovarian Cancer

G. Nisticó, Tatjana, D. Caracciolo, 2022 .

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma

P. Tassone, P. Tagliaferri, M. Arbitrio, 2023, Journal of Experimental & Clinical Cancer Research.

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

P. Tassone, P. Tagliaferri, D. Caracciolo, 2023, Journal of Translational Medicine.

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma

P. Tassone, P. Tagliaferri, A. Neri, 2021, Cancers.

Hit identification of novel small molecules interfering with MALAT1 triplex by a structure‐based virtual screening

P. Tassone, B. Pagano, Jussara Amato, 2023, Archiv der Pharmazie.